1 / 67

糖尿病治療新趨勢

糖尿病治療新趨勢. 時間: 2009-04-24 (09:00-10:30) 地點:花蓮高中 主講人:三軍總醫院 石光中主任 (MD, PhD). MANAGEMENT OF TYPE 2 DIABETES. ORAL ANTIDIABETIC AGENTS (OAD) INSULIN. MANAGEMENT OF TYPE 2 DIABETES. ORAL ANTIDIABETIC AGENTS (OAD) INSULIN. ORAL ANTIDIABETIC AGENTS.

elu
Download Presentation

糖尿病治療新趨勢

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. 糖尿病治療新趨勢 時間:2009-04-24 (09:00-10:30) 地點:花蓮高中 主講人:三軍總醫院 石光中主任(MD, PhD)

  2. MANAGEMENT OF TYPE 2 DIABETES • ORAL ANTIDIABETIC AGENTS (OAD) • INSULIN

  3. MANAGEMENT OF TYPE 2 DIABETES • ORAL ANTIDIABETIC AGENTS (OAD) • INSULIN

  4. ORAL ANTIDIABETIC AGENTS • Insulin secretagogues (sulfonylureas, meglitinides, D-phenylalanine derivatives) • Biguanides • Thiazolidinediones • α-glucosidase inhibitors • Pramlintide(Amylin) • Exenatide (GLP-1) • Sitagliptin (DPP-4 inhibitor)

  5. ORAL ANTIDIABETIC AGENTS • Insulin secretagogues (sulfonylureas, meglitinides, D-phenylalanine derivatives) • Biguanides • Thiazolidinediones • α-glucosidase inhibitors • Pramlintide(Amylin) • Exenatide (GLP-1) • Sitagliptin (DPP-4 inhibitor)

  6. 治療糖尿病的藥物(1)

  7. ORAL ANTIDIABETIC AGENTS • Insulin secretagogues (sulfonylureas, meglitinides, D-phenylalanine derivatives) • Biguanides • Thiazolidinediones • α-glucosidase inhibitors • Pramlintide(Amylin) • Exenatide (GLP-1) • Sitagliptin (DPP-4 inhibitor)

  8. 治療糖尿病的藥物(2)

  9. ORAL ANTIDIABETIC AGENTS • Insulin secretagogues (sulfonylureas, meglitinides, D-phenylalanine derivatives) • Biguanides • Thiazolidinediones • α-glucosidase inhibitors • Pramlintide(Amylin) • Exenatide (GLP-1) • Sitagliptin (DPP-4 inhibitor)

  10. 治療糖尿病的藥物(3)

  11. ORAL ANTIDIABETIC AGENTS • Insulin secretagogues (sulfonylureas, meglitinides, D-phenylalanine derivatives) • Biguanides • Thiazolidinediones • α-glucosidase inhibitors • Pramlintide(Amylin) • Exenatide (GLP-1) • Sitagliptin (DPP-4 inhibitor)

  12. 治療糖尿病的藥物(4)

  13. Thiazolidinediones Increase glucose uptake in skeletal muscle and decrease lipolysis in adipose tissue Meglitinides Increase insulin secretion from pancreatic -cells Biguanide (metformin) Decreases hepatic glucose production and increases uptake Sulfonylureas Increase insulin secretion from pancreatic -cells -Glucosidase inhibitors Delay intestinal carbohydrate absorption Pharmacologic targets of current drugs used in the treatment of T2DM Adapted from Cheng and Fantus. CMAJ. 2005;172:213–226.

  14. Traditional Type 2 Diabetes Management: A “Treat-to-Fail Approach” Published Conceptual Approach OAD plus multiple daily insulininjections Diet andexercise OAD monotherapy OAD up-titration OAD combination OAD plus basal insulin Mean HbA1cof patients 10 9 HbA1c, % 8 7 6 Time Duration of Diabetes OAD=oral anti-hyperglycaemic drug. Adapted from Campbell IW. Need for intensive, early glycaemic control in patients with type 2 diabetes. Br J Cardiol. 2000;7(10):625–631. Del Prato S et al. Int J Clin Pract. 2005;59:1345–1355. 12

  15. Major Side Effects of oral anti-diabetes drugs

  16. ORAL ANTIDIABETIC AGENTS • Insulin secretagogues (sulfonylureas, meglitinides, D-phenylalanine derivatives) • Biguanides • Thiazolidinediones • α-glucosidase inhibitors • Pramlintide(Amylin) • Exenatide (GLP-1) • Sitagliptin (DPP-4 inhibitor)

  17. PRAMLINTIDE • Pramlintide, a synthetic analog of amylin, is an injectable antihyperglycemic that modulates postprandial glucose levels and is approved for preprandial use in individuals with type 1 and type 2 diabetes. • Pramlintidesuppresses glucagon release via undetermined mechanisms, delays gastric emptying, and has central nervous system-mediated anorectic effects. • It is rapidly absorbed after subcutaneous administration; levels peakwithin 20 minutes, and the durationof action is not more than 150 minutes. • Pramlintide should be injected immediately before eating; doses range from 15 mcg to 120 mcg subcutaneously.

  18. PRAMLINTIDE • Therapy with this agent should be initiated with the lowest dose andtitrated upward. • Because of the risk of hypoglycemia, concurrent rapid- or short-acting mealtime insulin doses should be decreasedby 50% or more. • Pramlintide should always be injected by itself with a separate syringe; it cannot be mixed with insulin. • The major side effects of pramlintide are hypoglycemiaandgastrointestinal symptoms including nausea, vomiting, and anorexia.

  19. ORAL ANTIDIABETIC AGENTS • Insulin secretagogues (sulfonylureas, meglitinides, D-phenylalanine derivatives) • Biguanides • Thiazolidinediones • α-glucosidase inhibitors • Pramlintide(Amylin) • Exenatide (GLP-1) • Sitagliptin (DPP-4 inhibitor)

  20. The Incretin Approach

  21. Glucagon-like peptide-1 (GLP-1): a new approach for type 2 diabetes therapy

  22. GLP-1 and GIP Are the Two Major Incretins GLP-1=glucagon-like peptide 1; GIP=glucose-dependent insulinotropic polypeptide Adapted from Drucker DJ DiabetesCare 2003;26:2929–2940; Ahrén B Curr Diab Rep 2003;3:365–372; Drucker DJ Gastroenterology 2002;122:531–544; Farilla L et al Endocrinology 2003;144:5149–5158; Trümper A et al Mol Endocrinol 2001;15:1559–1570; Trümper A et al J Endocrinol 2002;174:233–246.

  23. 200 400 50 g glucose 150 300 Glucose (mg/dL) Insulin (pmol/L) 100 200 50 100 0 0 -30 0 30 60 90 120 150 180 210 -30 0 30 60 90 120 150 180 210 Time (min) Time (min) Insulin Secretion Increases Dramatically in Response to Oral Glucose Ingestion Oral Glucose Tolerance Test Adapted from Nauck MA, et al. J Clin Endocrinol Metab. 1986;63:492-8.

  24. 200 150 100 50 0 -30 0 30 60 90 120 150 180 210 Time (min) Oral IV Proof of a Gastrointestinal ‘Incretin Effect’: Different Responses to Oral vs. IV Glucose OGTT and Matched IV Infusion 400 300 Glucose (mg/dL) Insulin(pmol/L) 200 100 0 -30 0 30 60 90 120 150 180 210 Time (min) Adapted from Nauck MA, et al. J Clin Endocrinol Metab. 1986;63:492-8.

  25. Type 2 diabetes patients haveimpaired GLP-1 secretion n =33 n=54 Toft-Nielsen et al. J Clin Endocrinol Metab 2001;86:3717–3723

  26. Glucose (mg/dL) C-peptide (nmol/L) Glucagon (pmol/L) 300 30 3.0 GLP-1 infusion GLP-1 infusion GLP-1 infusion 250 25 2.5 * * 200 * 20 2.0 * * * 150 * 15 1.5 * * * 100 * 10 1.0 * * * * * GLP-1 50 5 0.5 Saline 0 0 0.0 –30 0 30 60 90 120 150 180 210 240 –30 –30 0 0 30 30 60 60 90 90 120 120 150 150 180 180 210 210 240 240 Time (min) Time (min) Time (min) GLP-1 Restores Islet Cell Glucose Sensing in T2DM *P < .05 GLP-1 = glucagon-like peptide–1; T2DM= type 2 diabetes mellitus Adapted from Nauck MA, et al. Diabetologia. 1993;36:741–744.

  27. GLP-1 has multiple desirableeffects • Stimulates insulin secretion • Preserves or increases β-cell mass in animal models • Decreases glucagon secretion • Delays gastric emptying • Induces satiety and decreases food intake • Beneficial effects on memory and learning in animal models

  28. GLP-1 is Rapidly Degraded by DPP-4 DPP-4  A G F S S V L G A H E T T D Y E S Q A 7 9 K A K F L R I V E W G G 37 T½ = 1–2 minutes *Amino acids shown in gold are homologous with the structure of glucagon.

  29. GLP-1 related agents • NN2211(Liraglutide) : long-acting GLP-1 derivative • Exenatide: synthetic exendin 4 compound • DPP-4 inhibitors

  30. GLP-1 related agents • NN2211(Liraglutide) : long-acting GLP-1 derivative • Exenatide: synthetic exendin 4 compound • DPP-4 inhibitors

  31. NN2211(Liraglutide) is a long-acting GLP-1 analogue 26 34 Knudsen et al. J Med Chem 2000;43:1664–1669

  32. GLP-1 related agents • NN2211(Liraglutide) long-acting GLP-1 derivative • Exenatide synthetic exendin 4 compound • DPP-4 inhibitors

  33. EXENATIDE • As a synthetic analog of glucagon-like-polypeptide 1 (GLP-1), exenatide is the first incretin therapy to become available for the treatment of diabetes. • In clinical studies, exenatide therapy is shown to have multiple actions such as potentiation of glucose-mediated insulin secretion, suppression of postprandial glucagon release through as-yet unknown mechanisms, slowed gastric emptying and a central loss of appetite. • Exenatide is absorbed equally from arm, abdomen, or thigh injection sites, reaching a peak concentration in approximately 2 hours with a duration of up to 10 hours.

  34. EXENATIDE • Exenatide is injected subcutaneously within 60 minutes before a meal; therapy is initiated at 5 mcg twice daily, with a maximum dosage of 10 mcg twice daily. • When exenatide is added to preexisting sulfonylurea therapy, the oral hypoglycemic dosage may need to be decreased to prevent hypoglycemia. • The major side effects are nausea (about 44% of users) and vomiting and diarrhea. The nausea decreases with ongoing exenatide usage.

  35. GLP-1 related agents • NN2211(Liraglutide) long-acting GLP-1 derivative • Exenatide synthetic exendin 4 compound • DPP-4 inhibitors

  36. Pancreatic Islet Cells are Targets for Incretin Hormones β-Cell α-Cell Foodintake Incretin Pancreatic Islet Incretin Response GLP-1=Glucagon-Like Peptide-1 Adapted from Drucker D. Diabetes Care. 2003;26:2929-2940. Wang Q, et al. Diabetologia. 2004;47:478-487.

  37. DPP-4 Inhibitors Mixed meal GLP-1 Inactive Intestinal GLP-1 release DPP-IV GLP-1 Active Rapid inactivation (>80% of pool) Plasma GLP-1 Actions Excreted by kidneys Improvement of glucose metabolic profile Mechanism of Action of DPP-4 Inhibitors Primary actions of GLP-1 - Promote insulin secretion (β- cell) - Reduce glucagon secretion/hepatic glucose production (α- cell)

  38. ProGIP Capillary GIP [1-42] Synthesis, Secretion, and Metabolism of GLP-1 and GIP L-Cell K-Cell Proglucagon GLP-1 [7-37] Capillary GLP-1 [7-36NH2] GIP [1-42] ACTIVE GLP-1[7-36NH2] ACTIVE DPP-4 DPP-4 • Dipeptidyl peptidase-4 (DPP-4) • Ubiquitous, specific protease • Cleaves N-terminal dipeptide • Inactivates > 50% of GLP-1 in ~ 1 min • > 50% of GIP in ~ 7 min GIP [3-42] INACTIVE GLP-1 [9-36NH2] INACTIVE

  39. Endocrine and neural pathways for GLP-1-mediated actions

  40. The Need for a More Comprehensive Approach for Treating Type 2 Diabetes

  41. ORAL ANTIDIABETIC DRUGS • Insulin secretagogues (sulfonylureas, meglitinides, D-phenylalanine derivatives) • Biguanides • Thiazolidinediones • α-glucosidase inhibitors • Pramlintide (Amylin) • Exenatide (GLP-1) • Sitagliptin (DPP-4 inhibitor)

  42. ↑insulin and ↓glucagon reduce hepatic glucose output GI tract X DPP-4 Inhibitor DPP-4 Inhibitors Improve Glucose Control by Increasing Incretin Levels in Type 2 Diabetes Ingestion of food • Glucose dependent • Insulin from beta cells(GLP-1 and GIP) Insulinincreases peripheral glucose uptake Pancreas Release of incretins from the gut β-cells Hyperglycemia Improved Physiologic Glucose Control α-cells DPP-4 Enzyme • Glucagon from alpha cells (GLP-1)Glucose dependent Inactive incretins DPP-4 = dipeptidyl peptidase 4 Adapted from Brubaker PL, Drucker DJ Endocrinology 2004;145:2653–2659; Zander M et al Lancet 2002;359:824–830; Ahrén B Curr Diab Rep 2003;3:365–372; Buse JB et al. In Williams Textbook of Endocrinology. 10th ed. Philadelphia, Saunders, 2003:1427–1483.

  43. SITAGLIPTIN • Sitagliptin is an inhibitor of dipeptidyl peptidase-4 (DPP-4), the enzyme that degrades incretin and other GLP-1-like molecules. • Control of hyperglycemia and reductions in HbA1c were documented at doses of 100 mg orally once daily. • Dosage should be reduced in patients with renal impairment. Hypoglycemic episodes were rare and the drug facilitated weight loss. • Sitagliptin therapy can be combined with metformin, TZDs, or sulfonylureas.

  44. Characteristics of an Ideal Therapy • Characteristics of an ideal oral antidiabetic agent • Lowers HbA1cto normal levels • Decreases insulin resistance and hepatic glucose production and increasesor preserves β-cell mass while restoring first-phase insulin response • Does not cause weight gain • Does not increase risk of hypoglycemia • Does not cause edema or congestive heart failure

  45. Combination Therapy Offers Advantages Over Monotherapy • Combination therapy may provide more glycemic control than the individual monotherapies • Combination therapy may provide more comprehensive coverage of the key pathophysiologies of type 2 diabetes than monotherapy • An appropriately chosen combination therapy may help more patients achieve their HbA1c goal without increasing side effects1 Adapted from Del Prato Int J Clin Pract 2005;59:1345-1355.

  46. MANAGEMENT OF TYPE 2 DIABETES • ORAL ANTIDIABETIC AGENTS (OAD) • INSULIN

  47. 胰島素種類(1)

  48. 胰島素種類(2)

  49. Introduction • Insulin replacement consists of 1. Prandial (bolus) insulin:mimic the response of endogenous insulin to food intake, but onlythe first phase of insulin secretion 2. The basal-insulin:mimics the relatively small but constant release of insulin 3.Correction-dose insulin supplement:addresses pre-meal or between-meal hyperglycemia, independentlyof the prandial insulin.

More Related